NBIX Earnings
Latest Revenue1.1B
Latest Net Income206.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q3 2026 | $2.03 | 1.1B | 206.5M | +41.2% | -3.8% |
| Q2 2026 | $1.43 | 959.0M | 144.4M | +39.5% | +31.2% |
| Q1 2026 | $1.97 | 814.5M | 197.9M | +42.2% | +2,362.5% |
| Q4 2025 | $1.54 | 805.5M | 153.7M | +28.3% | +49.5% |
| Q3 2025 | $2.11 | 794.9M | 209.5M | +27.8% | +64.8% |
| Q2 2025 | $1.09 | 687.5M | 107.5M | +16.5% | +70.3% |
| Q1 2025 | $0.08 | 572.6M | 7.9M | +11.1% | -81.4% |
| Q4 2024 | $1.03 | 627.7M | 103.1M | +21.8% | -31.3% |
| Q3 2024 | $1.28 | 622.1M | 129.8M | — | — |
| Q2 2024 | $0.64 | 590.2M | 65.0M | — | — |
| Q1 2024 | $0.43 | 515.3M | 43.4M | — | — |
| Q4 2023 | $1.50 | 515.2M | 147.7M | — | — |
Neurocrine Biosciences (NBIX) — Earnings